Elf Sanofi S.A. v the Upjohn Company

Elf Sanofi S.A. (Elf) sought to prevent The Upjohn Company (Upjohn) from infringing its Australian patent for a novel pharmaceutical compound, known as "Compound A," and its use in treating a particular disease. The dispute concerned the validity of Elf's patent, specifically whether the invention was obvious in light of prior art. The matter came before T. Williams J in the Federal Court of Australia.

The central legal issue before the Court was whether the invention claimed in Elf's patent was obvious to a person skilled in the art, having regard to the state of knowledge existing before the priority date of the patent. This required an assessment of the prior art documents and the extent to which they disclosed or suggested the claimed invention, and whether the inventive step was sufficiently demonstrated.

T. Williams J applied the principles established in cases such as *Monsanto Australia Ltd v. Commissioner of Patents* and *Bristol-Myers Squibb Company v. FH Faulding & Co Ltd*. His Honour considered the nature of the skilled person, the scope of their knowledge, and the approach they would take when faced with the problem addressed by the patent. The Court found that the prior art did not contain a clear and unambiguous disclosure or suggestion that would have led the skilled person to Compound A and its therapeutic use, thereby concluding that the invention possessed the necessary inventive step and was not obvious.

The Court therefore found that Elf's patent was valid and that Upjohn had infringed it.